Changing Promotional Spend
Big Pharma's investment in drug promotion between 1998-2001 increased nearly three times as fast in the US as in the largest European market, and in absolute terms was more than 12 times higher in 2001. European restrictions on promotional spend and a continent-wide ban on DTC advertising severely limit the benefits of promotion there. The progression of marketing spend in individual European markets varies, however.
You may also be interested in...
Drug price fixing throughout Europe has long frustrated the pharmaceutical industry, but Pfizer's CEO has singled out France as the worst perpetrator.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.